GSK continues to make use of Peakdale's synthetic chemistry abilities, and have expanded the agreement to include support for GSK's cardiovascular and urogenital centre of excellence
Peakdale Molecular announces the extension of its agreement with GlaxoSmithKline (GSK) to provide ongoing services for the Respiratory and Inflammation Centre of Excellence for Drug Discovery (RI CEDD).
Under the extension of the agreement through 2005, GSK continues to make use of Peakdale's synthetic chemistry abilities, and have expanded the agreement to include support for GSK's cardiovascular and urogenital (CVU) CEDD.
Kim Morrison, Peakdale CEO, commented, "Peakdale is known for its abilities to devise new synthetic routes to challenging compounds in a flexible and responsive service, delivering on time and in full.
"This revised agreement gives GSK continuation of a dedicated team of chemists for the duration of the projects."
